Heron Slogan

My image

AirXpanders closes $10 M investment round and initiates U.S. Clinical study
January 23, 2012

AirXpanders Inc., a company developing innovative products addressing the breast and burn reconstruction markets, secured $10 million in Series D financing. Investors include Vivo Ventures, GBS Venture Partners, Heron Capital and Prolog Ventures.

This round will fund the ongoing U.S. Investigational Device Exemption (IDE) study for the AeroFormâ„¢ Patient Controlled Tissue Expander System.

Scott Dodson, CEO, said the company has already seen "great success" in the IDE study, with no adverse events reported to date.

Our Team








© Copyright 2018 Heron Capital